Skip to main content

What the FDA labels say about taking them together

Aliskiren and benazepril

Benazepril's FDA label of September 30, 2025 names aliskiren in its contraindications section; aliskiren's label does not name benazepril itself but warns about its class (ACE inhibitors). The benazepril label: “Do not coadminister aliskiren with angiotensin receptor blockers, ACE inhibitors, including Lotensin in patients with diabetes.”

Check it at the source: the aliskiren FDA label on DailyMed (effective March 7, 2024, LXO US Inc.); the benazepril FDA label on DailyMed (effective September 30, 2025, Validus Pharmaceuticals LLC).

What does the aliskiren label say about benazepril?

Aliskiren's label does not name benazepril itself; it warns about its class (ACE inhibitors):

Aliskiren label, warnings and precautions

In general, avoid combined use of Tekturna with ACE inhibitors or ARBs, particularly in patients with creatinine clearance (CrCl) less than 60 mL/min [see Contraindications ( 4 ), Drug Interactions ( 7 ) and Clinical Studies ( 14.3 )].

Aliskiren label, drug interactions

In general, avoid combined use of aliskiren with ACE inhibitors or ARBs, particularly in patients with CrCl less than 60 mL/min.

Source: FDA drug label (Tekturna), NDA021985 (Lxo Ireland), as published by LXO US Inc., effective March 7, 2024 (SPL set 3dd61fa5-1620-4ebf-bbdb-ede29b92fce2), via openFDA; the full label on DailyMed

What does the benazepril label say about aliskiren?

Benazepril label, contraindications

Do not coadminister aliskiren with angiotensin receptor blockers, ACE inhibitors, including Lotensin in patients with diabetes [see Drug Interactions (7.4) ].

Benazepril label, drug interactions

Blockade of the Renin-Angiotensin System (RAS) Dual Blockade of the RAS with angiotensin receptor blockers, ACE inhibitors, or aliskiren is associated with increased risks of hypotension, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy.

Source: FDA drug label (Lotensin), Validus Pharmaceuticals LLC, effective September 30, 2025 (SPL set 2abb091b-a53e-46b0-9b84-e5ee8f2bdd8e), via openFDA; the full label on DailyMed

These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.

Both medicines on the record

1Aliskiren generic labelers
21Benazepril generic labelers
AliskirenBenazepril
Labeled forHigh blood pressureHigh blood pressure
Boxed warningYesYes
Pharmacy cost (NADAC)$3.94 per tablet 150 mg tablet$0.0789 per tablet 20 mg tablet
Shortage nowNo current entryNo current entry

Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)

What next?